Propofol protects H9C2 cells against hypoxia/reoxygenation injury through miR‑449a and NR4A2

Qian,Qiu; Xie,Yingxiang

doi:10.3892/etm.2021.10615

Propofol protects H9C2 cells against hypoxia/reoxygenation injury through miR‑449a and NR4A2

Authors:
- Qiu Qian
- Yingxiang Xie
View Affiliations

Affiliations: Department of Anesthesiology, Children's Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China
Published online on: August 16, 2021 https://doi.org/10.3892/etm.2021.10615
Article Number: 1181
Copyright: © Qian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Propofol has been revealed to protect cardiomyocytes against myocardial ischemia injury, although the underlying mechanism remains incompletely understood. H9C2 cells were used to generate a hypoxia/reoxygenation (H/R) in vitro model for the present study. Reverse transcription‑quantitative PCR and western blotting were performed to measure the expression levels of microRNA (miR)‑449a and nuclear receptor subfamily 4 group A member 2 (NR4A2). The CCK‑8, BrdU, EdU, and caspase‑3 activity assays and western blot analysis were employed to detect cell viability, proliferation, and apoptosis. The target relationship between miR‑449a and NR4A2 was verified through dual‑luciferase reporter assays. The results confirmed that exposure of the cells to H/R resulted in severe cell injury. However, the presence of propofol improved cell activity by promoting cell viability and proliferation and inhibiting cell apoptosis. The beneficial effect of propofol on H/R‑mediated injury could be abrogated by the inhibition of NR4A2 mediated by miR‑449a. Thus, the present study demonstrated that propofol counteracted cardiomyocyte H/R injury by inhibiting miR‑449a to upregulate NR4A2.

View Figures

View References

1	Nadatani Y, Watanabe T, Shimada S, Otani K, Tanigawa T and Fujiwara Y: Microbiome and intestinal ischemia/reperfusion injury. J Clin Biochem Nutr. 63:26–32. 2018.PubMed/NCBI View Article : Google Scholar
2	Binder A, Ali A, Chawla R, Aziz HA, Abbate A and Jovin IS: Myocardial protection from ischemia-reperfusion injury post coronary revascularization. Expert Rev Cardiovasc Ther. 13:1045–1057. 2015.PubMed/NCBI View Article : Google Scholar
3	Ferdinandy P, Schulz R and Baxter GF: Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 59:418–458. 2007.PubMed/NCBI View Article : Google Scholar
4	Zhao ZQ and Vinten-Johansen J: Postconditioning: Reduction of reperfusion-induced injury. Cardiovasc Res. 70:200–211. 2006.PubMed/NCBI View Article : Google Scholar
5	Qiao SG, Sun Y, Sun B, Wang A, Qiu J, Hong L, An JZ, Wang C and Zhang HL: Sevoflurane postconditioning protects against myocardial ischemia/reperfusion injury by restoring autophagic flux via an NO-dependent mechanism. Acta Pharmacol Sin. 40:35–45. 2019.PubMed/NCBI View Article : Google Scholar
6	Li Z, Zhang Y, Ding N, Zhao Y, Ye Z, Shen L, Yi H and Zhu Y: Inhibition of lncRNA XIST improves myocardial I/R injury by targeting miR-133a through inhibition of autophagy and regulation of SOCS2. Mol Ther Nucleic Acids. 18:764–773. 2019.PubMed/NCBI View Article : Google Scholar
7	Yao L, Chen H, Wu Q and Xie K: Hydrogen-rich saline alleviates inflammation and apoptosis in myocardial I/R injury via PINK-mediated autophagy. Int J Mol Med. 44:1048–1062. 2019.PubMed/NCBI View Article : Google Scholar
8	Li W, Li Y, Chu Y, Wu W, Yu Q, Zhu X and Wang Q: PLCE1 promotes myocardial ischemia-reperfusion injury in H/R H9c2 cells and I/R rats by promoting inflammation. Biosci Rep. 39(BSR20181613)2019.PubMed/NCBI View Article : Google Scholar
9	Lotz C, Stumpner J and Smul TM: Sevoflurane as opposed to propofol anesthesia preserves mitochondrial function and alleviates myocardial ischemia/reperfusion injury. Biomed Pharmacother. 129(110417)2020.PubMed/NCBI View Article : Google Scholar
10	Li YM, Sun JG, Hu LH, Ma XC, Zhou G and Huang XZ: Propofol-mediated cardioprotection dependent of microRNA-451/HMGB1 against myocardial ischemia-reperfusion injury. J Cell Physiol. 234:23289–23301. 2019.PubMed/NCBI View Article : Google Scholar
11	Li H, Zhang X, Tan J, Sun L, Xu LH, Jiang YG, Lou JS, Shi XY and Mi WD: Propofol postconditioning protects H9c2 cells from hypoxia/reoxygenation injury by inducing autophagy via the SAPK/JNK pathway. Mol Med Rep. 17:4573–4580. 2018.PubMed/NCBI View Article : Google Scholar
12	Zhao D, Li Q, Huang Q, Li X, Yin M, Wang Z and Hong J: Cardioprotective effect of propofol against oxygen glucose deprivation and reperfusion injury in H9c2 cells. Oxid Med Cell Longev. 2015(184938)2015.PubMed/NCBI View Article : Google Scholar
13	Vasileiou I, Xanthos T, Koudouna E, Perrea D, Klonaris C, Katsargyris A and Papadimitriou L: Propofol: A review of its non-anaesthetic effects. Eur J Pharmacol. 605:1–8. 2009.PubMed/NCBI View Article : Google Scholar
14	Green TR, Bennett SR and Nelson VM: Specificity and properties of propofol as an antioxidant free radical scavenger. Toxicol Appl Pharmacol. 129:163–169. 1994.PubMed/NCBI View Article : Google Scholar
15	Hanouz JL, Yvon A, Flais F, Rouet R, Ducouret P, Bricard H and Gérard JL: Propofol decreases reperfusion-induced arrhythmias in a model of ‘border zone’ between normal and ischemic-reperfused guinea pig myocardium. Anesth Analg. 97:1230–1238. 2003.PubMed/NCBI View Article : Google Scholar
16	Hu S, Cao S, Tong Z and Liu J: FGF21 protects myocardial ischemia-reperfusion injury through reduction of miR-145-mediated autophagy. Am J Transl Res. 10:3677–3688. 2018.PubMed/NCBI
17	Yang Y, Yang J, Liu XW, Ding JW, Li S, Guo X, Yang CJ, Fan ZX, Wang HB, Li Q, et al: Down-regulation of miR-327 alleviates ischemia/reperfusion-induced myocardial damage by targeting RP105. Cell Physiol Biochem. 49:1049–1063. 2018.PubMed/NCBI View Article : Google Scholar
18	Ye Y, Hu Z, Lin Y, Zhang C and Perez-Polo JR: Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res. 87:535–544. 2010.PubMed/NCBI View Article : Google Scholar
19	Cheng J, Wu Q, Lv R, Huang L, Xu B, Wang X, Chen A and He F: MicroRNA-449a inhibition protects H9C2 cells against hypoxia/reoxygenation-induced injury by targeting the Notch-1 signaling pathway. Cell Physiol Biochem. 46:2587–2600. 2018.PubMed/NCBI View Article : Google Scholar
20	Zhang X, Dong H, Liu Y, Han J, Tang S and Si J: Tetramethylpyrazine partially relieves hypoxia-caused damage of cardiomyocytes H9c2 by downregulation of miR-449a. J Cell Physiol, Feb 15, 2019 (Epub ahead of print).
21	Spathis AD, Asvos X, Ziavra D, Karampelas T, Topouzis S, Cournia Z, Qing X, Alexakos P, Smits LM, Dalla C, et al: Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease. Proc Natl Acad Sci USA. 114:3999–4004. 2017.PubMed/NCBI View Article : Google Scholar
22	Medzikovic L, Schumacher CA, Verkerk AO, van Deel ED, Wolswinkel R, van der Made I, Bleeker N, Cakici D, van den Hoogenhof MM, Meggouh F, et al: Orphan nuclear receptor Nur77 affects cardiomyocyte calcium homeostasis and adverse cardiac remodelling. Sci Rep. 5(15404)2015.PubMed/NCBI View Article : Google Scholar
23	Xiao G, Sun T, Songming C and Cao Y: NR4A1 enhances neural survival following oxygen and glucose deprivation: An in vitro study. J Neurol Sci. 330:78–84. 2013.PubMed/NCBI View Article : Google Scholar
24	Liu H, Liu P, Shi X, Yin D and Zhao J: NR4A2 protects cardiomyocytes against myocardial infarction injury by promoting autophagy. Cell Death Discov. 4(27)2018.PubMed/NCBI View Article : Google Scholar
25	Lucchinetti E, Hofer C, Bestmann L, Hersberger M, Feng J, Zhu M, Furrer L, Schaub MC, Tavakoli R, Genoni M, et al: Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery: Inhalational versus intravenous anesthetics. Anesthesiology. 106:444–457. 2007.PubMed/NCBI View Article : Google Scholar
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
27	Ming N, Na HST, He JL, Meng QT and Xia ZY: Propofol alleviates oxidative stress via upregulating lncRNA-TUG1/Brg1 pathway in hypoxia/reoxygenation hepatic cells. J Biochem. 166:415–421. 2019.PubMed/NCBI View Article : Google Scholar
28	Kim EJ, Choi IS, Yoon JY, Park BS, Yoon JU and Kim CH: Effects of propofol-induced autophagy against oxidative stress in human osteoblasts. J Dent Anesth Pain Med. 16:39–47. 2016.PubMed/NCBI View Article : Google Scholar
29	Wang Z, Yang P and Qi Y: Role of microRNA-134 in the neuroprotective effects of propofol against oxygen-glucose deprivation and related mechanisms. Int J Clin Exp Med. 8:20617–20623. 2015.PubMed/NCBI
30	Ma K, Qiu J, Zhou M, Yang Y and Ye X: Cox-2 Negatively affects the protective role of propofol against hypoxia/reoxygenation induced cardiomyocytes apoptosis through suppressing Akt signaling. Biomed Res Int. 2019(7587451)2019.PubMed/NCBI View Article : Google Scholar
31	Xu B, Zhang X, Wang S and Shi B: MiR-449a suppresses cell migration and invasion by targeting PLAGL2 in breast cancer. Pathol Res Pract. 214:790–795. 2018.PubMed/NCBI View Article : Google Scholar
32	Liu J, Yu F, Wang S, Zhao X, Jiang F, Xie J and Deng M: circGFRA1 promotes ovarian cancer progression by sponging miR-449a. J Cancer. 10:3908–3913. 2019.PubMed/NCBI View Article : Google Scholar
33	Kardys I, van Tiel CM, de Vries CJ, Pannekoek H, Uitterlinden AG, Hofman A, Witteman JC and de Maat MP: Haplotypes of the NR4A2/NURR1 gene and cardiovascular disease: The Rotterdam Study. Hum Mutat. 30:417–423. 2009.PubMed/NCBI View Article : Google Scholar